SCHEMBL8071365

SCHEMBL8071365

C=C(Nc1cccc(OC)c1)c1ccc(C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
TP53 P04637 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
KMT2A Q03164 2/20 0.56
PKM P14618 1/20 0.56
RXFP1 Q9HBX9 1/20 0.54
TSHR P16473 2/20 0.54
NFKB1 P19838 2/20 0.54
NFKB2 Q00653 2/20 0.54
RELA Q04206 2/20 0.54
KDM4E B2RXH2 1/20 0.54
NLRP3 Q96P20 1/20 0.52
TRPV1 Q8NER1 1/20 0.51
KCNK3 O14649 1/20 0.51
KCNK9 Q9NPC2 1/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8086822 0.84 ROCK2 (0.55) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL8079371 0.84 NPC1 (0.65) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL8086791 0.83 NPC1 (0.51) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL8091906 0.82 NPC1 (0.56) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL31179863 0.82 NPC1 (0.83) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL4252397 0.82 NPC1 (0.83) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL3622291 0.82 NPC1 (0.58) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL13391762 0.81 KMT2A (0.69) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL8086755 0.78 RAB9A (0.50) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL5852120 0.77 TP53 (0.82) NPC1RAB9ATP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed